Hematologic Malignancy
B-Cell Non-Hodgkin Lymphoma
CI-CAN-00000471Explore in graph →
Hematologic1,757 active trials43 approved drugs73 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00000471Explore in graph →
Clinical trials
6,183 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (954)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00325416 | Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. | completed | Phase 1 / Phase 2 | 177 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 14, 2018 | clinicaltrials |
| NCT01217957 | A Study of Ixazomib Administered in Combination With Lenalidomide and Low-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 65 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 |
| Mar 14, 2018 |
| clinicaltrials |
| NCT00201877 | Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma | completed | Phase 2 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT00963534 | Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.(LENA-BERIT) | completed | Phase 1 / Phase 2 | 51 | Lund University HospitalOTHER | 4 | Mar 12, 2018 | clinicaltrials |
| NCT01453205 | A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | completed | Phase 2 | 187 | MedImmune LLCINDUSTRY | 11 | Mar 12, 2018 | clinicaltrials |
| NCT01622439 | Valproate as First Line Therapy in Combination With Rituximab and CHOP in Diffuse Large B-cell Lymphoma(VALFRID) | completed | Phase 1 / Phase 2 | 50 | Lund University HospitalOTHER | 1 | Mar 12, 2018 | clinicaltrials |
| NCT01737177 | Bendamustine/Lenalidomide/Rituximab: Combination as a Second-Line Therapy for 1st Relapsed-Refractory MCL(R2-B) | completed | Phase 2 | 42 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 9, 2018 | clinicaltrials |
| NCT01313611 | BRIEF Bendamustine and Rituximab In Elderly Follicular(BRIEF) | terminated | Phase 2 | 62 | The Lymphoma Academic Research OrganisationOTHER | 2 | Mar 7, 2018 | clinicaltrials |
| NCT01547806 | Collection of Transplant Stem Cells for Plasma Cell Myeloma | completed | Phase 2 | 49 | National Cancer Institute (NCI)NIH | 1 | Mar 7, 2018 | clinicaltrials |
| NCT00253630 | Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Mar 6, 2018 | clinicaltrials |
| NCT01365559 | Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments | completed | Phase 1 / Phase 2 | 39 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01792102 | Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple Myeloma | unknown | Phase 1 / Phase 2 | 38 | OncotherapeuticsINDUSTRY | 1 | Mar 5, 2018 | clinicaltrials |
| NCT00287872 | Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma | completed | Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Mar 1, 2018 | clinicaltrials |
| NCT00375791 | Efficacy of Perifosine Alone and in Combination With Dexamethasone for Patients With Multiple Myeloma | completed | Phase 2 | 67 | AEterna ZentarisINDUSTRY | 1 | Feb 28, 2018 | clinicaltrials |
| NCT00401011 | Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients | completed | Phase 1 / Phase 2 | 84 | AEterna ZentarisINDUSTRY | 0 | Feb 23, 2018 | clinicaltrials |
| NCT01147393 | Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma | terminated | Phase 1 / Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Feb 22, 2018 | clinicaltrials |
| NCT00639002 | A Study to Determine the Effect and Safety of an Oral Janus Kinase 2 (JAK2)-Inhibitor (Ruxolitinib; INBC018424) in Patients With Multiple Myeloma | completed | Phase 2 | 13 | Incyte CorporationINDUSTRY | 1 | Feb 13, 2018 | clinicaltrials |
| NCT01315873 | Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma | terminated | Phase 2 | 24 | NYU Langone HealthOTHER | 1 | Feb 7, 2018 | clinicaltrials |
| NCT00003512 | Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia | withdrawn | Phase 2 | 0 | Burzynski Research InstituteOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01675141 | Lenalidomide Maintenance Therapy for Multiple Myeloma | terminated | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01446900 | R-2cda and Prolongation of Therapy With Rituximab Alone in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma | terminated | Phase 2 | 25 | European Institute of OncologyOTHER | 1 | Jan 31, 2018 | clinicaltrials |
| NCT01472887 | SAR3419 as Single Agent in Relapsed-Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients(STARLYTE) | completed | Phase 2 | 61 | SanofiINDUSTRY | 9 | Jan 25, 2018 | clinicaltrials |
| NCT01335685 | Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 61 | Millennium Pharmaceuticals, Inc.INDUSTRY | 5 | Jan 23, 2018 | clinicaltrials |
| NCT01441973 | Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma | completed | Phase 2 | 41 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 23, 2018 | clinicaltrials |
| NCT02983097 | Therapy of Non-Hodgkin-Lymphoma by Combination of Lenalidomide + Rituximab, Dexa, High-dose ARA-C and CisP(R²-DHAP) | terminated | Phase 1 / Phase 2 | 34 | Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbHOTHER | 1 | Jan 19, 2018 | clinicaltrials |
| NCT00185614 | Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma | completed | Phase 2 | 63 | Wen-Kai WengOTHER | 1 | Jan 18, 2018 | clinicaltrials |
| NCT01564277 | Rasburicase and Allopurinol in Treating Patients With Hematologic Malignancies | terminated | Phase 2 | 24 | Roswell Park Cancer InstituteOTHER | 1 | Jan 9, 2018 | clinicaltrials |
| NCT02363439 | Extension Study of IMO-8400 in Patients With Waldenström's Macroglobulinemia Who Completed Study 8400-401 | completed | Phase 1 / Phase 2 | 5 | Idera Pharmaceuticals, Inc.INDUSTRY | 0 | Jan 9, 2018 | clinicaltrials |
| NCT03392714 | Bendamustine-based Combination Therapy for PCNSL | unknown | Phase 2 | 15 | Chonnam National University HospitalOTHER | 1 | Jan 8, 2018 | clinicaltrials |
| NCT03391739 | CART-19 Cells For R/R B-ALL(CCFRRBA) | unknown | Phase 2 / Phase 3 | 20 | Fujian Medical UniversityOTHER | 1 | Jan 5, 2018 | clinicaltrials |
| NCT00867529 | Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma | completed | Phase 2 | 63 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2018 | clinicaltrials |
| NCT01270932 | Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients | completed | Phase 2 | 28 | University Health Network, TorontoOTHER | 1 | Dec 29, 2017 | clinicaltrials |
| NCT01332617 | Phase II Study of Simvastatin for Relapsed/Refractory Myeloma | withdrawn | Phase 2 | 0 | University of LouisvilleOTHER | 0 | Dec 29, 2017 | clinicaltrials |
| NCT03322735 | Study of BCMA CAR-T in Multiple Myeloma | unknown | Phase 1 / Phase 2 | 10 | Henan Cancer HospitalOTHER_GOV | 1 | Dec 29, 2017 | clinicaltrials |
| NCT00963872 | Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer | terminated | Phase 1 / Phase 2 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00422656 | Perifosine in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia | completed | Phase 2 | 37 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 26, 2017 | clinicaltrials |
| NCT03383406 | A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma(IVAM) | unknown | Phase 2 | 30 | Asan Medical CenterOTHER | 0 | Dec 26, 2017 | clinicaltrials |
| NCT01083602 | Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma(MACS1271) | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 21, 2017 | clinicaltrials |
| NCT00461045 | Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 15 | CelgeneINDUSTRY | 1 | Dec 19, 2017 | clinicaltrials |
| NCT03100877 | Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma | withdrawn | Phase 1 / Phase 2 | 0 | City of Hope Medical CenterOTHER | 1 | Dec 13, 2017 | clinicaltrials |
| NCT00349778 | High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma | completed | Phase 2 | 102 | Stanford UniversityOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT01057225 | Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma | completed | Phase 1 / Phase 2 | 64 | Mayo ClinicOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT02252146 | Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation | completed | Phase 1 / Phase 2 | 6 | Idera Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 12, 2017 | clinicaltrials |
| NCT00764517 | Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 57 | OHSU Knight Cancer InstituteOTHER | 1 | Dec 11, 2017 | clinicaltrials |
| NCT00060424 | Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia | completed | Phase 2 | 21 | Fred Hutchinson Cancer CenterOTHER | 2 | Dec 8, 2017 | clinicaltrials |
| NCT02229981 | Early Phase Evaluation of ABC294640 in Patients With Refractory/Relapsed Diffuse Large B-cell Lymphoma or Kaposi Sarcoma(ABC-102) | withdrawn | Phase 1 / Phase 2 | 0 | RedHill Biopharma LimitedINDUSTRY | 1 | Dec 7, 2017 | clinicaltrials |
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00556452 | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | completed | Phase 1 / Phase 2 | 46 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01343368 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | terminated | Phase 2 | 19 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
Data updated 24 days agoSource updated Mar 14, 2018source: clinicaltrials